Cost analysis of a randomized stem cell mobilization study in multiple myeloma

Show full item record



Permalink

http://hdl.handle.net/10138/229285

Citation

Varmavuo , V , Silvennoinen , R , Anttila , P , Saily , M , Sankelo , M , Putkonen , M , Ahonen , J , Mahlamaki , E , Mantymaa , P , Savolainen , E-R , Remes , K & Jantunen , E 2016 , ' Cost analysis of a randomized stem cell mobilization study in multiple myeloma ' , Annals of Hematology , vol. 95 , no. 10 , pp. 1653-1659 . https://doi.org/10.1007/s00277-016-2772-1

Title: Cost analysis of a randomized stem cell mobilization study in multiple myeloma
Author: Varmavuo, Ville; Silvennoinen, Raija; Anttila, Pekka; Saily, Marjaana; Sankelo, Marja; Putkonen, Mervi; Ahonen, Jouni; Mahlamaki, Eija; Mantymaa, Pentti; Savolainen, Eeva-Riitta; Remes, Kari; Jantunen, Esa
Contributor organization: Department of Oncology
Clinicum
Hematologian yksikkö
Department of Medicine
Date: 2016-10
Language: eng
Number of pages: 7
Belongs to series: Annals of Hematology
ISSN: 0939-5555
DOI: https://doi.org/10.1007/s00277-016-2772-1
URI: http://hdl.handle.net/10138/229285
Abstract: Upfront autologous stem cell transplantation (ASCT) is the standard therapy for younger multiple myeloma (MM) patients. MM patients usually undergo stem cell mobilization with cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF), or with G-CSF alone. A limited number of randomized studies are available comparing costs of different mobilization strategies. Eighty transplant-eligible patients aged up to 70 years with untreated MM were included in this prospective study. The patients were treated with RVD induction for three 21-day cycles and randomized 1: 1 at inclusion into one of the two mobilization arms CY 2 g/m(2) + G-CSF [arm A] vs. G-CSF alone [arm B]. Plerixafor was given according to a specific algorithm if needed. Sixty-nine patients who received mobilization followed by blood graft collection were included in the cost analysis. The median total costs of the mobilization phase were significantly higher in arm A than in arm B (3855 (sic) vs. 772 (sic), p
Subject: Stem cell mobilization
Autologous stem cell transplantation
Multiple myeloma
Cost analysis
Cyclophosphamide
Plerixafor
COLONY-STIMULATING FACTOR
PLUS G-CSF
LOW-DOSE CYCLOPHOSPHAMIDE
TRANSPLANTATION
PLERIXAFOR
CHEMOTHERAPY
STRATEGIES
GUIDELINES
EFFICACY
OUTCOMES
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
art_3A10.1007_2Fs00277_016_2772_1.pdf 312.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record